Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Lonza will supply Clovis drug
by Ann M. Thayer
November 7, 2016
| A version of this story appeared in
Volume 94, Issue 44
Contract manufacturer Lonza will build a plant in Visp, Switzerland, to supply rucaparib, the active ingredient in Clovis Oncology’s PARP inhibitor. Lonza will open a new production line in 2019 that will provide dedicated supply until 2025. Rucaparib targets cancer by inhibiting the DNA-repair enzymes poly-ADP ribose polymerase-1, 2, and 3. It is under FDA priority review for treating advanced ovarian cancer with a decision to come by February 2017.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X